Aurobindo Pharma arm gets US FDA nod for posaconazole injection; share up 1.6%
The product is anticipated to be launched in December 2023, the approved product is estimated to target a market size of $25.4 million.
The product is anticipated to be launched in December 2023, the approved product is estimated to target a market size of $25.4 million.
Aurobindo Pharma has received approval from USFDA to produce and trade Budesonide Inhalation Suspension